Do NAD+ boosters help or hurt sleep? What NMN and NR trials can tell us

A sleep promise needs a sleep result

For someone buying an NAD+ booster because nights have become difficult, the useful question is whether a comparable product improved a comparable sleep problem. The available studies discussed here provide mixed, preliminary answers. A favorable NMN questionnaire finding coexists with a timing trial that did not show a sleep-quality interaction and an NR trial without a sleep advantage over its randomized comparison. [1, 2, 3]

I would therefore treat a claim of better sleep as a separate proposition from higher NAD. Before opening a checkout, name the problem: falling asleep, waking repeatedly, daytime drowsiness or feeling unrefreshed. Those are different questions to bring to a qualified clinician. A product promising cellular energy should not silently become a treatment for all of them.

What the positive NMN result actually supports

Morifuji and colleagues randomized sixty older adults to NMN or placebo for twelve weeks. Global Pittsburgh Sleep Quality Index scores and daytime dysfunction were lower in the NMN group at twelve weeks. These were secondary findings; the primary stepping endpoint did not differ between groups. The authors also noted that recruitment did not specifically select people with sleep difficulties. ^[1]

That is a reason to investigate further, with the study’s boundaries intact. It is not a trial of every NMN bottle or a demonstrated treatment for clinical insomnia. Our Morifuji study companion examines the paper’s full endpoint hierarchy. Here, its role is to show why a promising sleep signal can matter without becoming a universal purchase recommendation.

The timing trial does not establish a bedtime rule

Kim and colleagues studied 108 older Japanese adults in four groups: morning NMN, afternoon NMN and the corresponding placebo groups. Across twelve weeks, sleep quality measured by the PSQI showed no statistically significant group-by-time interaction. Drowsiness improved within both afternoon groups, including placebo. The trial excluded people with treated insomnia and regular use of sleeping drugs or antidepressants. ^[2]

I would not turn those results into a best-time-to-take instruction. Improvement within one group does not establish that its schedule outperformed the matching placebo. Nor should a finding about drowsiness be relabeled as deeper sleep. The timing-study companion retains the four groups so the favorable phrases remain attached to their comparisons.

Three trials, three different answers

A higher NAD number can coexist with unchanged sleep

In a 58-person long-COVID trial, Wu and colleagues found that NR increased blood NAD but the randomized comparisons did not show a sleep benefit. Post hoc analyses combining NR exposure periods found some improvement from baseline. Substantial dropout and multiple exploratory comparisons limit that interpretation. Long COVID is also a specific clinical setting, not a stand-in for every sleep complaint. ^[3]

This is the distinction I would keep on the page when a product cites the study. The meaningful purchase question concerns how you sleep, not just whether a blood measurement moves. Our long-COVID trial companion explains the analysis choices, and the biomarker guide makes the wider distinction visible.

Can a booster make sleep worse?

The NR trial’s adverse-event table recorded two worsening-insomnia reports in the continuous-NR group, both judged unrelated, and worsening-sleep reports in both groups; one in the continuous-NR group was judged possibly related. These small counts do not establish a predictable insomnia risk or exclude individual reactions. The comparison group later received NR, so an overall event table is not a simple placebo-only incidence comparison. ^[3]

I would take a new sleep complaint seriously without declaring its cause from timing alone. Keep a factual record of the exact ingredient, formulation, when it was introduced and what changed, then discuss it with your care team. Customer stories can suggest a question worth asking; they cannot supply a reliable probability that a product will improve or disrupt your nights.

Questionnaires and clinical insomnia need separate claims

A sleep questionnaire is evidence about reported sleep experience. It does not by itself demonstrate a change in sleep stages, establish the cause of a complaint or show that a diagnosed disorder has resolved. A published chronic-insomnia NMN study protocol describes an intended randomized experiment, rather than completed efficacy results. A plan to test a treatment should not be quoted as proof that it works. ^[4]

The same discipline applies to mechanisms involving circadian pathways. A biological explanation can motivate research, but it cannot replace a human comparison that measures the relevant outcome. I would ask a seller to identify the completed study and the exact sleep endpoint before accepting a broad sleep-support claim. This article is a focused reading of selected primary studies, rather than a systematic review of every possible precursor or sleep intervention.

Keep injections and oral precursors in different columns

All three completed trials above used oral precursors. Their findings do not demonstrate that an NAD+ injection, infusion, spray or direct-NAD liquid improves sleep. FDA has separately warned about serious reactions after NAD+ injectables consistent with excessive endotoxins. That is a preparation-quality concern, not proof of an oral sleep effect or a comparison of individual providers. ^[5]

For a product comparison, use the label worksheet to retain the ingredient and full formulation. For a clinical service, use the compounded NAD+ questions. My purchase judgment is to pause a sleep-led purchase when the supporting citation does not match the product and complaint. A meaningful next step is a clinical discussion of the sleep problem, with the proposed product clearly identified.

One useful test is to ask what information would change the purchase decision. If the answer is a completed trial in people with the same complaint, request that trial before committing. If the answer is simply that the liquid is easier to swallow or the bottle has clearer terms, record it as a practical preference. Keeping those reasons visible helps prevent an understandable desire for better nights from becoming confidence in a benefit the cited research has not established.